Related Experiment Video
Updated: Jun 28, 2026

Mouse Kidney Transplantation: Models of Allograft Rejection
Published on: October 11, 2014
Nox-2 is a modulator of fibrogenesis in kidney allografts
A Djamali1, A Vidyasagar, M Adulla
1Nephrology Section, Department of Medicine, University of Wisconsin Madison School of Medicine and Public Health, Madison, WI, USA. axd@medicine.wisc.edu
Abstract:
We studied the role of classical phagocytic NADPH oxidase (Nox) in the pathogenesis of kidney allograft tubulointerstitial fibrosis. Immunofluorescence studies showed that Nox-2 and p22phox (electron transfer subunits of Nox) colocalized in the tubulointerstitium of human kidney allografts. Tubular Nox-2 also colocalized with alpha-SMA in areas of injury, suggestive of epithelial-to-mesenchymal transition (EMT). Interstitial macrophages (CD68(+)) and myofibroblasts (alpha-SMA(+)) expressed Nox-2 while graft infiltrating T cells (CD3(+)) and mature fibroblasts (S100A4(+)) were Nox-2(-). These results were confirmed in the Fisher-to-Lewis rat kidney transplant model. Areas of tubulitis were associated with Nox-2 and alpha-SMA, suggestive of EMT. Immunoblot analyses showed that Nox-2 upregulation was associated with oxidative stress (nitrotyrosine) and fibrogenesis (alpha-SMA and phospho-Smad2) at 3 weeks and 6 months. Allografts treated with Nox inhibitors (DPI or apocynin) for 1 week showed reduced fibronectin and phospho-Smad2 and increased E-cadherin levels. Cyclosporine A, TGF-beta1 and angiotensin II increased Nox-2 mRNA levels 2- to 7-fold in vitro (NRK52E cells). Treatment with specific Nox inhibitors (DPI or apocynin) prevented the downregulation of E-cadherin and upregulation of fibronectin transcripts. In aggregate, these studies suggest that Nox-2 is involved in the pathogenesis of allograft tubulointerstitial fibrosis via activation transcription factor Smad2, EMT and myofibroblasts.
Insights
The study reveals that NADPH oxidase 2 (Nox-2) drives kidney allograft tubulointerstitial fibrosis by promoting oxidative stress and epithelial-to-mesenchymal transition (EMT). Inhibiting Nox-2 reduces fibrosis markers and improves graft health.
Area of Science:
- Nephrology
- Immunology
- Molecular Biology
Background:
- Kidney allograft tubulointerstitial fibrosis is a major cause of graft loss.
- The role of NADPH oxidase (Nox) enzymes in this process remains incompletely understood.
Purpose of the Study:
- To investigate the role of classical phagocytic NADPH oxidase (Nox) in kidney allograft tubulointerstitial fibrosis.
- To elucidate the specific Nox isoforms and cellular sources involved in fibrosis development.
Main Methods:
- Immunofluorescence staining for Nox-2, p22phox, alpha-SMA, and other markers in human and rat kidney allografts.
- In vitro studies using NRK52E cells treated with Cyclosporine A, TGF-beta1, and angiotensin II.
- Treatment of allografts with Nox inhibitors (DPI, apocynin) and assessment of fibrosis markers.
Main Results:
- Nox-2 and p22phox colocalized in fibrotic areas of human and rat kidney allografts.
- Nox-2 expression was elevated in interstitial macrophages and myofibroblasts, correlating with oxidative stress and fibrogenesis markers.
- Nox inhibition reduced fibrosis markers (fibronectin, phospho-Smad2) and promoted epithelial markers (E-cadherin).
- Pro-fibrotic stimuli increased Nox-2 mRNA, which was reversed by Nox inhibitors.
Conclusions:
- Nox-2 plays a significant role in the pathogenesis of kidney allograft tubulointerstitial fibrosis.
- Nox-2 contributes to fibrosis through activation of Smad2, promotion of epithelial-to-mesenchymal transition (EMT), and myofibroblast activation.
- Targeting Nox-2 may represent a therapeutic strategy to mitigate kidney allograft fibrosis.
Related Concept Videos
Kidney Transplant II: Surgical Procedure
Acute Kidney Injury II: Pathophysiology
Kidney Transplant III: Nursing Management
Nephrons
Kidney Transplant I: Introduction
Nephrotic Syndrome II : Assessment and Medical Management
